These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3622947)

  • 21. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological properties of colloidal bismuth subcitrate (CBS, DE-NOL).
    Wieriks J; Hespe W; Jaitly KD; Koekkoek PH; Lavy U
    Scand J Gastroenterol Suppl; 1982; 80():11-6. PubMed ID: 6962539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De-Nol: mucosal protection and peptic ulcer disease. Proceedings of the De-Nol Symposium. September 8th, 1986, 8th World Congress of Gastroenterology, São Paulo.
    Digestion; 1987; 37 Suppl 2():1-64. PubMed ID: 3622944
    [No Abstract]   [Full Text] [Related]  

  • 24. Colloidal bismuth subcitrate in non-ulcer dyspepsia.
    Khanna MU; Abraham P; Nair NG; Mistry FP; Vora IM
    J Postgrad Med; 1992; 38(3):106-8. PubMed ID: 1303406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absorption of bismuth from two bismuth compounds before and after healing of peptic ulcers.
    Hundal O; Bergseth M; Gharehnia B; Andersen KJ; Berstad A
    Hepatogastroenterology; 1999; 46(29):2882-6. PubMed ID: 10576366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro.
    Slomiany BL; Nishikawa H; Bilski J; Slomiany A
    Am J Gastroenterol; 1990 Apr; 85(4):390-3. PubMed ID: 2109526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance therapy with colloidal bismuth subcitrate reduces duodenal ulcer relapse.
    Bardhan KD; Singh S; Morris P; Thompson M; Hinchliffe RF; Cary BA; Wall RM; Blakemore CB
    Ital J Gastroenterol Hepatol; 1997 Apr; 29(2):128-34. PubMed ID: 9646192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double blind randomised study of tripotassium-di-citrato-bismuthate in the treatment of peptic ulcer.
    Tripathi BM; Misra NP; Dube S
    J Assoc Physicians India; 1984 Nov; 32(11):964-5. PubMed ID: 6396295
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer.
    Vantrappen G; Schuurmans P; Rutgeerts P; Janssens J
    Scand J Gastroenterol Suppl; 1982; 80():23-30. PubMed ID: 6761849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis.
    Marshall BJ; Armstrong JA; Francis GJ; Nokes NT; Wee SH
    Digestion; 1987; 37 Suppl 2():16-30. PubMed ID: 3622946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bismuth revisited in Helicobacter pylori gastro-duodenal infection].
    Caron F; Rouveix B
    Therapie; 1991; 46(5):393-8. PubMed ID: 1754987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative study of the efficacy of De-Nol and ranitidine in treating duodenal ulcer].
    Oproiu A; Pospai D; Cociaşu S; Oproiu C
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(4):375-84. PubMed ID: 2905519
    [No Abstract]   [Full Text] [Related]  

  • 33. Bismuth absorption from 205Bi-labelled pharmaceutical bismuth compounds used in the treatment of peptic ulcer disease.
    Dresow B; Fischer R; Gabbe EE; Wendel J; Heinrich HC
    Scand J Gastroenterol; 1992 Apr; 27(4):333-6. PubMed ID: 1589712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of colloidal bismuth subcitrate tablets and ranitidine in the treatment of chronic duodenal ulcers.
    Ward M; Halliday C; Cowen AE
    Digestion; 1986; 34(3):173-7. PubMed ID: 3530861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial].
    Karateev AE; Nasonov EL; Radenska-Lopovok SG
    Ter Arkh; 2005; 77(2):46-9. PubMed ID: 15807452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori.
    Goodwin CS; Marshall BJ; Blackbourn SJ; Warren JR; Phillips M
    J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662
    [No Abstract]   [Full Text] [Related]  

  • 37. [Skin disorders caused by bismuth oxide (De-Nol)].
    Ottervanger JP; Stricker BH
    Ned Tijdschr Geneeskd; 1994 Jan; 138(3):152-3. PubMed ID: 8295642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosa protectives: sucralfate and colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN; Nio CY
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():152-61. PubMed ID: 3660894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure of colloidal bismuth subcitrate (CBS) in dilute HCl: unique assembly of bismuth citrate dinuclear units ([Bi(cit)(2)Bi](2-)).
    Li W; Jin L; Zhu N; Hou X; Deng F; Sun H
    J Am Chem Soc; 2003 Oct; 125(41):12408-9. PubMed ID: 14531674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Gastroduodenal ulcer and Campylobacter pylori. Behavior under treatment with de-nol or metronidazole].
    Velasco Elizalde C; Quintero Díaz M; Soto Escobar A; Buesa Muñoz F; González Cansino J; Haedo Quiñones W
    G E N; 1987; 41(3):99-103. PubMed ID: 3149943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.